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The integrin heterodimer CD11b/CD18 (aMb2, Mac-1,
CR3) expressed on monocytes or polymorphonuclear
leukocytes (PMN) is a receptor for iC3b, fibrinogen,
heparin, and for intercellular adhesion molecule
(ICAM)-1 on endothelium, crucially contributing to
vascular cell interactions in inflammation and athero-
sclerosis. In this report, we summarize our findings on
the effects of lipid mediators and lipid-lowering drugs.
Exposure of endothelial cells to oxidized low density
lipoprotein (oxLDL) induces upregulation of ICAM-1
and increases adhesion of monocytic cells expressing
Mac-1. Inhibition experiments show that monocytes
use distinct ligands, i.e. ICAM-1 and heparan sulfate
proteoglycans for adhesion to oxLDL-treated endothe-
lium. An albumin-transferable oxLDL activity is inhib-
ited by the antioxidant pyrrolidine dithiocarbamate
(PDTC), while 8-epi-prostaglandin F2a (8-epi-PGF2a)
or lysophosphatidylcholine had no effect, implicating
yet unidentified radicals. Sequential adhesive and sig-
naling events lead to the firm adhesion of rolling PMN
on activated and adherent platelets, which may oc-
cupy areas of endothelial denudation. Shear-resistant
arrest of PMN on thrombin-stimulated platelets in
flow conditions requires distinct regions of Mac-1, in-
volving its interactions with fibrinogen bound to plate-
let aIIbb3, and with other platelet ligands. Both arrest
and adhesion strengthening under flow are stimulated
by platelet-activating factor and leukotriene B4, but
not by the chemokine receptor CXCR2. We tested
whether Mac-1-dependent monocyte adhesiveness is
affected by inhibitors of hydroxy-methylglutaryl-Co-
enzyme A reductase (statins) which improve morbid-
ity and survival of patients with coronary heart dis-
ease. As compared to controls, adhesion of isolated
monocytes to endothelium ex vivo was increased in
patients with hypercholesterolemia. Treatment with
statins decreased total and low density lipoprotein
(LDL) cholesterol plasma levels, surface expression of
Mac-1, and resulted in a dramatic reduction of Mac-1-
mediated monocyte adhesion to endothelium. The in-
hibition of monocyte adhesion was reversed by meval-
onate but not LDL in vitro, indicating that isoprenoid
precursors are crucial for adhesiveness of Mac-1. Such
effects may crucially contribute to the clinical benefit
of statins, independent of cholesterol-lowering, and
may represent a paradigm for novel, anti-inflamma-
tory mechanisms of action by this class of drugs.
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Monocyte Adhesion to Oxidized Low Density 
Lipoprotein-Stimulated Endothelium Mediated 
by Distinct Ligands
The process of atherogenesis involves the actions of
oxidized low density lipoprotein (oxLDL). An extensive
oxidative modification of LDL may occur in an antioxi-
dant-depleted subendothelial microenvironment (1).
OxLDL can induce the initial adhesiveness and transmi-
gration of human blood monocytes or monocytic cell
lines on vascular endothelium, possibly enhancing
monocyte recruitment and retention (2–5). In addition,
stimulation of endothelial cells with oxLDL has been re-
ported to increase adhesion of human blood monocy-
tes (6). However, the mechanisms involved in this ef-
fect remain to be completely elucidated. Studies in
human umbilical vein endothelial cells (HUVEC) have
demonstrated that intercellular adhesion molecule
(ICAM)-1 expression is upregulated by oxLDL or by
long-term incubation with native LDL (6, 7). Two novel
endothelial adhesion proteins for monocytic cells have
recently been described to be induced by minimally
modified LDL (mmLDL) (8, 9). We have shown that the
human monocytic cell line Mono Mac 6 (10) is an ap-
propriate in vitro tool to study monocyte interactions
with cytokine-stimulated endothelium (11). In the fol-
lowing section, we have summarized findings on the
adhesion of Mono Mac 6 cells to oxLDL-stimulated HU-
VEC, in an attempt to characterize the endothelial 
ligands involved in this interaction and to identify 
responsible active components in the oxLDL prepara-
tions used.
Treatment of HUVEC with oxLDL for 24 hours dose-
dependently increases the adhesion of human mono-
cytic Mono Mac 6 cells but not of U937 cells. Mac-1
(CD11b/CD18), a monocytic counter-receptor for ICAM-
1 that also binds to heparin (12), is present on Mono
Mac 6 but not U937 cells, and may thus explain these
differences in adhesion (11). Consistently, oxLDL in-
duces a two-fold upregulation of ICAM-1 but not vas-
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cular cell adhesion molecule (VCAM)-1 or E-selectin
surface expression on HUVEC. Maltose-1-phosphate
(M1P) or heparin but not monoclonal antibodies
(mAbs) to ICAM-1 reduce Mono Mac 6 cell adhesion to
untreated HUVEC. Induction of unidentified endothelial
molecules by mmLDL has been suggested to mediate
monocyte adhesion, as inferred by inhibition with M1P
(13), and this may explain the lack of inhibition with
ICAM-1 mAbs. Notably, combinations of mAbs to
ICAM-1 with either M1P or heparin, a recently identi-
fied Mac-1 ligand (12), inhibited Mono Mac 6 adhesion
to oxLDL-stimulated HUVEC by more than 50 %, while
either alone had no effect. This suggests that two dis-
tinct endothelial ligands for Mac-1, inducible ICAM-1
and heparan sulfate proteoglycans, mediate monocyte
interaction with oxLDL-treated HUVEC. The composi-
tion of oxLDL particles is subjected to considerable
variation (1). Our preparations are thoroughly washed
in EDTA-containing phosphate buffer saline (PBS) after
oxidation, comparable to dialyzing. Consistently, toxic
effects (e.g. lactate dehydrogenase (LDH) elevation or
detachment) are detectable after 24 hours incubation
of HUVEC with unwashed but not washed oxLDL. The
extraction of oxLDL components by treatment with bo-
vine serum albumin (BSA) and subsequent separation
results in diminished activity of oxLDL and a transfer of
active components to BSA, as indicated by the induc-
tion of ICAM-1 expression and monocyte adhesion.
However, candidate lipid peroxidation products, lyso-
phosphatidylcholine (LPC) or 8-epi PGF2a which have
been reported as active components in oxLDL (14, 15),
produce no stimulatory effects. Thus, formation of
other oxidation products is responsible for the activity
of oxLDL, and the identification of such compounds is
currently underway. Multiple radicals and peroxides
are generated during the oxidation processes, and
presence of the antioxidant and radical scavenger pyr-
rolidine dithiocarbamate (PDTC) prevents induction of
Mono Mac 6 cell adhesion in oxLDL-stimulated HUVEC,
likely due to co-antioxidative, radical scavenging prop-
erties. In conclusion, oxidatively modified LDL induces
adhesion of monocytic cells, which utilize at least two
distinct ligands on endothelium, identified as ICAM-1
when sufficiently upregulated and heparan proteogly-
cans (16). This may provide a possible mechanism for
atherogenic effects of oxLDL.
Similarly, an upregulation of ICAM-1 by oxLDL has
been described in HUVEC or porcine coronary artery en-
dothelium (6, 17). In contrast, mmLDL appears to de-
crease endothelial ICAM-1 expression (13). This may be
due to differences in cell culture conditions and LDL
preparation as evident from the distinct electrophoretic
mobility of mmLDL and oxLDL. The late time point of
ICAM-1 induction by oxLDL has not been previously
noted, in part due to toxic effects on prolonged incuba-
tion (6). Using washed oxLDL may be comparable to
long-term incubation with native LDL protected against
extensive cellular oxidation, which also enhances ICAM-
1 expression (7). Both effects may be due to induction of
secondary endothelial mediators, resulting in a delayed
ICAM-1 upregulation. Consistently, recent studies in a
rat model have shown that the injection of LDL is asso-
ciated with the appearance of vascular reactivity for
oxLDL epitopes and endothelial ICAM-1 expression on
endothelium after 24 hours (18). In addition, expression
of ICAM-1 on endothelium subsequently serves to sup-
port dynamically regulated and lymphocyte function as-
sociated-1 (LFA-1)-mediated transmigration of monocy-
tes (Figure 1), e.g. in response to monocyte chemotactic
protein-1 (MCP-1) (19).
A clear inhibition of monocyte adhesion to oxLDL-
stimulated HUVEC with ICAM-1 mAbs requires their
combination with M1P or heparin, indicating an essen-
tial involvement of at least two distinct endothelial li-
gands in increased monocyte adhesion, i.e. ICAM-1 fol-
lowing initial upregulation by oxLDL and heparan
sulfate proteoglycans (16). Consistently, ICAM-1 mAb
only slightly inhibits monocyte adhesion to oxLDL-
treated vascular smooth muscle cells despite induction
of ICAM-1, and blocking one endothelial ligand margi-
nally affects monocyte binding to cytokine-stimulated
HUVEC, whereas combinations of mAbs cause strong
inhibition (20, 21), indicating that alternative ligands
can compensate for blocking one interaction. An inhibi-
tion of adhesion with M1P in combination with ICAM-1
mAbs suggests a contribution of ligands for monocy-
tes, which are also induced by mmLDL and can be
blocked with M1P (14). Distinct endothelial ligands in-
duced by mmLDL (8, 9) do not appear to be identical
with such ligands (16), since they mediate U937 adhe-
sion, which is not increased by oxLDL. An inhibition of
monocyte adhesion with the soluble Mac-1 ligand hep-
arin (12) indicates that cellular heparan sulfate proteo-
glycans are involved in monocyte adhesion to untreated
HUVEC. While heparin alone has no effect, combining
heparin with ICAM-1 mAbs significantly inhibits mono-
cyte adhesion to oxLDL-stimulated HUVEC. This indi-
cates that, in addition to ICAM-1, the presence of such
heparan sulfate proteoglycans is required to mediate
monocytic cell adhesion to oxLDL-stimulated HUVEC,
emphasizing the involvement of at least two distinct li-
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Fig. 1 Distinct ligands induced by oxLDL on endothelium in-
volved in monocyte adhesion and transmigration. GRO,
growth-stimulatory activity; ICAM-1, intercellular cell adhe-
sion molecule-1; LFA-1 lymphocyte function associated-1,
CD11a/CD18 integrin; Mac-1, CD11b/CD18 integrin; MCP-1,
monocyte chemotactic protein-1; oxLDL, oxidized low-density
lipoprotein.
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gands. Heparin can release and neutralize heparan-
bound chemokines such as growth-stimulating activity
(GRO), but not MCP-1, both of which are induced by
mmLDL and are involved in mediating monocyte adhe-
sion (22, 23). GRO may participate in the heparin-inhi-
bitable adhesion, since heparin inhibits adhesion to un-
treated endothelium where little GRO is expressed (22).
The endothelial ligands for monocytes induced by
oxLDL are schematically depicted in Figure 1.
The properties of the oxLDL preparations used ap-
pear to resemble those of LDL modified by coincuba-
tion with cultured cells (17). In search for active compo-
nents in oxLDL, we found that physiologically relevant
concentrations of 8-epi PGF2a (14) do not enhance
monocytic cell adhesion to HUVEC. In contrast to previ-
ous studies (15, 24), LPC does not contribute to the ef-
fects of oxLDL. This is consistent with results showing
that effects of oxLDL are not necessarily mediated by
LPC (25). Optimal treatment with LPC requires binding
to BSA (24), causing differences in effectiveness. The
transfer of active components in oxLDL to BSA indi-
cates the presence of lipophilic oxidation products
other than LPC, such as lipid peroxides or radicals, that
are responsible for induction of ICAM-1 and monocyte
adhesion. This is also supported by the prevention of
oxLDL-induced effects with PDTC, a potent radical
scavenger (20). Recently, it has been demonstrated that
oxLDL activates peroxisome proliferator-activated re-
ceptor g (PPARg )-dependent transcription through a
novel signaling pathway involving scavenger receptor-
mediated particle uptake, and two of the major oxi-
dized lipid components of oxLDL, 9-hydroxy octadeca-
dienoic acid (9-HODE) and 13-HODE, have been
identified as endogenous activators and ligands of
PPAR g (26). Such ligand activation can induce changes
characteristic of monocytic differentiation and pro-
mote uptake of oxLDL through transcriptional induc-
tion of the scavenger receptor CD36 (27). This may be
relevant to the signal transduction following activation
by oxLDL in endothelial cells, which may be mediated
by endothelial CD36 as a receptor binding oxLDL (28).
Taken together, our data suggest that washed oxLDL
without cytotoxicity upregulates ICAM-1 on endothe-
lium and induces monocyte adhesion that can be medi-
ated by ICAM-1 and additional endothelial ligands (16).
The induction of ICAM-1 and the involvement of hepa-
ran sulfate proteoglycans in adhesion could further ex-
plain the atherogenic potential of oxLDL and may lead
to the development of potential therapeutic strategies
in the prevention of atherogenesis.
Involvement of Platelet-Activating Factor (PAF) and
Leukotriene B4 (LTB4) in Leukocyte Arrest on Adher-
ent Platelets
In attempt to define the process of transendothelial leu-
kocyte extravasation, a multistep model has proposed
a sequential involvement of various traffic signal mole-
cules. Selectins initiate tethering and rolling of leuko-
cytes as a prerequisite for their stable arrest due to
stimulation of b 2 integrins in flow (29, 30). Platelets ex-
press P-selectin, which is mobilized from a -granules to
the plasma membrane upon activation, and the b 2 inte-
grin ligand ICAM-2 (31–33). Thus, a similar multistep
model may apply to the highly efficient accumulation
of PMN on surface-adherent platelets under flow. In-
deed, rolling and arrest of PMN on activated platelets
under flow requires the action of P-selectin and b 2 inte-
grins, respectively (34–37). Fibrinogen, a Mac-1 ligand
(38, 39) which can bind to activated platelets via a IIbb 3
(40), has been implicated in platelet-PMN interactions
in cell suspension or whole blood (41). However, the
role of Mac-1 in adherence of PMN in flow and the iden-
tity of the b 2 integrin ligands mediating PMN arrest on
activated platelets in flow remain to be elucidated.
Chemoattractants and CXC chemokines have been
shown to stimulate adhesiveness of Mac-1 in PMN (42,
43) and convert selectin-mediated rolling of PMN into
firm arrest (29). Interactions of PMN and platelets are
required for the production of certain chemokines, and
for transcellular leukotriene and arachidonic acid me-
tabolism by lipoxygenases (44). Activated platelets
produce chemoattractants, e.g. the lipid mediator leu-
kotriene B4 (LTB4) or the hydrolytic phospholipid prod-
uct, platelet-activating factor (PAF), which may stimu-
late PMN integrins. Platelets express the CXC
chemokines ENA-78, GRO-a and b -thromboglobulin, a
precursor for neutrophil activating peptide-2 (NAP-2)
released from a -granules and processed by cathepsin
G (45-47), which act via the receptor CXCR2 on PMN
(48). The receptor for PAF and the CXCR2 differ in sig-
nal transduction and coupling to Ga proteins (49).
Moreover, lipid mediators but not CXC chemokines are
soluble in the plasma membrane, while chemokines
but not lipid mediators bind to heparin or proteogly-
cans. This might lead to a differential role for these
chemoattractants in activation of PMN under flow.
We studied the pathways that lead to arrest and firm
adhesion of rolling PMN on activated, surface-adher-
ent platelets (50). Stable arrest and adhesion strength-
ening of PMN on thrombin-stimulated, surface-adher-
ent platelets in flow requires distinct Ca2+- and
Mg2+-dependent regions of Mac-1 (a Mb 2) and involves
interactions of Mac-1 with fibrinogen bound to plate-
lets via a IIbb 3. Mac-1 also binds to unidentified ligands
on platelets other than ICAM-2, heparin or heparan sul-
fate proteoglycans, as seen by inhibition with mAbs or
peptides, treatment of platelets with heparitinase and
by using platelets with defective a IIbb 3 from a patient
with Glanzmann thrombasthenia (50). Tethering of
PMN on platelet ICAM-2 via LFA-1 may facilitate the
transition between rolling on selectins and Mac-1-de-
pendent arrest. Chemoattractants and chemokines
stimulate the avidity of Mac-1 in PMN (43,44) and may
convert selectin-mediated rolling into firm arrest (29).
Hence, chemoattractive lipid mediators may play a role
in accumulation and adhesion strengthening of PMN
on activated platelets in flow. Pretreatment of PMN
with the PAF receptor antagonist UK-74,505 (51) results
in a dose-dependent inhibition of PMN accumulation
(50). The LTB4 receptor antagonist SC-53228 is less po-
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tent, while no additive effects are seen with both anta-
gonists over UK-74,505 alone. Likewise, pertussis toxin
(PTX) inhibits accumulation and shows little additive
effect with UK-74,505, whereas pretreatment with the
CXCR2 mAb 10H2 did not inhibit arrest. Similar effects
were seen for adhesion strengthening (50). UK-74,505,
SC-53228 and pertussis toxin PTX but not CXCR2 mAb
reduced the shear resistance of PMN adhesion and in-
creased rolling. Contrasting effects were obtained for
spreading of PMN on activated platelets in stasis. Thus,
PMN arrest and adhesion strengthening on activated
platelets under flow conditions appeared to be stimu-
lated by PAF and, to a lesser extent, LTB4 via PTX-sen-
sitive signaling pathways but not by activation of
CXCR2 (50).
It has been intriguing to apply a multistep model to
the highly efficient accumulation of PMN on activated,
surface-adherent platelets in flow. Rolling mediated by
P-selectin is important as a prerequisite for firm attach-
ment, and rolling on activated platelets was rapidly fol-
lowed by Mac-1 mediated arrest on fibrinogen (50). We
suggest that distinct functional regions of Mac-1 con-
tribute to PMN arrest and adhesion strengthening on
activated platelets in flow. Seven N-terminal repeats of
integrin a subunits have been predicted to fold into a b -
propeller structure containing putative Ca2+-binding
motifs located on the lower face, and the I or inserted
domain with a Mg2+ at its binding site to be tethered to
the top of this structure (52). The arrest of PMN may in-
volve Ca2+-dependent regions of Mac-1, in particular a
putative b -propeller domain, while the Mg2+-depen-
dent regions in the I domain may contribute to PMN ar-
rest on activated platelets. Taken together, Mac-1 may
be functionally subdivided into regions which contrib-
ute to initial arrest and regions which are required for
subsequent shear resistance in flow (50).
Arrest and adhesion strengthening of PMN on plate-
lets in flow appears to be stimulated by the lipid medi-
ators PAF and, to a lesser extent, LTB4, via PTX-sensi-
tive signaling pathways, but not by activation of CXCR2
(50). Several reasons may account for differential effec-
tiveness of platelet chemoattractants during PMN acti-
vation in shear flow. Firstly, lipid mediators but not CXC
chemokines are soluble in the lipid membrane,
whereas chemokines but not lipid mediators can be
bound to proteoglycans. The differential binding of
chemokines to proteoglycan subpopulations may de-
termine the presence and distribution of chemokines in
the cellular microenvironment (53). Thus, PAF or LTB4
may be retained in the platelet plasma membrane by
partition, whereas relevant platelet CXC chemokines
may not be bound to platelet proteoglycans, and may
be washed away under flow. Moreover, PMN enzymes
required for processing platelet precursors into active
CXC chemokines (47) may not be immobilized and may
be removed by flow. This would be consistent with in-
hibition of adhesion strengthening and spreading by
the CXCR2 mAb in stasis but not in flow. Alternatively,
the PAF receptor may differ from CXCR2 in its PTX-sen-
sitive signal transduction pathways and coupling to G a
proteins (48), which may enable a more rapid activa-
tion of Mac-1 adhesiveness under flow conditions. In
parallel, endothelial PAF has been implicated in juxta-
crine stimulation of integrin function in PMN tethered
through P-selectin on thrombin-stimulated endothe-
lium (54). Although P-selectin itself does not trigger ar-
rest of PMN under flow, it may cooperate with chemo-
attractants to stimulate leukocytes (55). It has recently
been confirmed that PMN adhesion on immobilized
platelets under shear flow requires both a juxtacrine
activation mechanism involving PAF and an enhancing
signal from P-selectin (56). Finally, Mac-1 and homolo-
gous interactions of platelet-endothelial cell adhesion
molecule-1 (PECAM-1) may contribute to transmigra-
tion of PMN through platelet layers, e.g. towards IL-8,
thus completing extravasation (37). Figure 2 illustrates
the multistep model with a sequential involvement of
signal molecules including PAF in the efficient accumu-
lation of PMN on adherent platelets under shear flow
conditions.
The proposed mechanisms of PMN arrest on acti-
vated, adherent platelets contribute to a more elaborate
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Fig. 2 Sequential involvement of signal molecules in accu-
muation of neutrophils on adherent platelets under shear
flow. ICAM-2, intercellular cell adhesion molecule-2; LFA-1
lymphocyte function associated-1, CD11a/CD18 integrin;
LTB4, leukotriene B4; Mac-1, CD11b/CD18 integrin; PAF, plate-
let-activating factor; PSGL-1, P-selectin glycoprotein-ligand 1;
PECAM-1, platelet-endothelial cell adhesion molecule-1.
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definition of the multistep model by demonstrating a
differential involvement of integrins, their ligands and
of chemoattractive lipid mediators in sequential steps
of this process. Interactions between platelets and leu-
kocytes occur at sites of vascular damage, as in hemo-
stasis. Platelets bind to prothrombotic endothelium
and the underlying basement membrane in vascular in-
jury, occupying a position analogous to the endothe-
lium. Binding of PMN to platelets immobilized in a
thrombus may facilitate immigration into thrombosed
areas, wound healing, tissue repair, or protection from
infection, and may contribute to the maintenance of
vascular integrity, as well as to its impairment in patho-
logical states. Platelets and PMN indeed colocalize at
sites of hemorrhage, vascular grafts, atherosclerotic le-
sions and myocardial infarction (57–60). Activation of
PMN and platelet adhesion occurs after coronary an-
gioplasty and is associated with late clinical events (61).
Understanding the mechanisms of PMN accumulation
on platelets in flow may thus lead to clinical applica-
tions and interventions to influence the consequences
of leukocyte-platelet interactions in vascular disease.
Statins Inhibit Monocyte Adhesiveness in Patients
with Hypercholesterolemia
Inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A
reductase (statins) are used in the treatment of hyper-
cholesterolemia. They also improve the survival of pa-
tients with coronary heart disease (CHD) and prevent
CHD in hypercholesterolemic men (62, 63). However,
the clinical benefit of 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors, such as simvastatin and
pravastatin, is not strictly correlated to their lipid lower-
ing effects (62, 64). The action of statins on cellular cho-
lesterol biosynthesis in the liver, blood cells, and vas-
culature may affect membrane integrity and regulation
of membrane-related processes (65) which are asso-
ciated with changes in multiple cellular functions. Cho-
lesterol precursors, i.e. farnesyl or geranyl pyrophos-
phates, have been implicated in interactions of
proteins and protein anchoring to lipid membranes (66,
67), essentially contributing to receptor-stimulated
Ca2+-increase, superoxide anion formation, LDL oxida-
tion, eicosanoid synthesis and differentiation in mono-
cytic cells (68-71). Functional consequences of such ef-
fects may be relevant for CHD and atherosclerosis.
Monocyte recruitment into the vascular wall is crucial
for initiation and progression of atherosclerotic lesions
(58). Interaction of the monocytic surface receptor Mac-
1 with ICAM-1 has been involved in the adhesion to and
migration across endothelium of monocytes, particu-
larly when stimulated (5, 30). Hence, we studied effects
of 3-hydroxy-3-methylglutaryl coenzyme A reductase
inhibitors on monocyte CD11b surface expression and
adhesion to endothelium in vitro, as well as on in-
creased adhesiveness of monocytes (72) isolated from
hypercholesterolemic patients before and after choles-
terol-lowering treatment, using a recently established
ex vivo assay with fixed human endothelial cells (73).
In hypercholesterolemic patients, Mac-1-dependent
adhesion of isolated monocytes to fixed endothelium
expressing ICAM-1 ex vivo is dramatically increased,
as compared to healthy controls. Treatment of these
patients with the 3-hydroxy-3-methylglutaryl coen-
zyme A reductase inhibitors lovastatin or simvastatin
for 6 weeks decreases total and LDL cholesterol plasma
levels, as well as monocyte CD11b surface expression,
and results in a substantial reduction of monocyte ad-
hesion to endothelium (74). The regulation of CD11b
surface expression is dissociated from adhesive func-
tion, which requires its activation (75, 76). Thus, the
pronounced decrease in adhesion after treatment with
statins appears to be independent of the slight reduc-
tion in CD11b expression. Adhesiveness of Mac-1 may
rather be mediated by a small subpopulation of mole-
cules undergoing conformational changes in response
to stimulation (77). Moreover, treatment of monocytes
with lovastatin in vitro dose-dependently reduces sur-
face expression of CD11b on monocytes, and inhibits
CD11b-dependent adhesiveness to fixed endothelium
of monocytes stimulated with MCP-1. Coincubation
with mevalonate, but not LDL, reverses these effects
(74), suggesting that early cholesterol precursors but
not cholesterol are crucial for adhesiveness of CD11b.
Hence, lovastatin may interfere with activation of 
Mac-1 adhesiveness by chemokines in monocytes, due
to decreased availability of isoprenoids.
Monocyte accumulation following adhesion to endo-
thelium and extravasation plays a crucial role in ather-
oma formation due to a perpetuation of chronic in-
flammatory reaction and lipid deposition into 
monocyte-derived foam cells (58). These cells further
contribute to the instability and disruption of atheroscle-
rotic plaques by secreting metalloproteases that de-
grade extracellular matrix constituents, and may thus
trigger clinical manifestations of atherosclerosis (78).
Isoprenoids posttranslationally modify various proteins
and mediate protein-membrane anchoring and interac-
tions of proteins. Some of the isoprenylated proteins
identified are small guanosine triphosphate (GTP)-bind-
ing proteins of the ras family, such as rac and rho, as well
as the g -subunits of heterotrimeric G-proteins (67).
Chemoattractant-receptors are coupled to G-protein
heterotrimers, and integrin-dependent binding of leuko-
cytes to endothelium can involve a G-protein regulated
activation event (30). Lovastatin has been shown to in-
hibit Ca2+-influx stimulated by G-protein-coupled recep-
tors and localization of ras-like proteins into the mem-
brane of monocytic cells (68). Expression of a
constitutively active form of the GTPase R-ras results in
activation of b 1 and b 3 integrin avidity, and inactivation
of the GTPase rho suggests its participation in signaling
via chemoattractant receptors to trigger activation of
Mac-1 (79, 80). Hence, statins may impair activation of
Mac-1 involving small GTPases, or stimulation of G-pro-
tein-heterotrimer coupled receptors by MCP-1 or other
autocrine chemokines. Alternatively, these drugs may
act by interfering with the transport, dimerization or an-
choring of Mac-1 in the plasma membrane to maintain
its cell surface expression. Statins may affect GTP-bind-
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ing protein-membrane or protein interactions by pre-
venting their prenylation or farnesylation, thus impair-
ing activation and expression of Mac-1.
Increased adhesion of monocytes to endothelium ex
vivo occurs in hypercholesteremic patients, however
inhibitory effects of statins have not been demon-
strated (72). The use of fixed endothelium from one
preparation allows to minimize interassay variations,
particularly in longitudinal adhesion studies (73), and
may have thus enabled us to detect inhibitory effects of
statins on monocyte adhesion. The increased adhesion
of monocytes from hypercholesterolemic patients has
been attributed to abnormal monocyte function with
respect to eicosanoid metabolism and superoxide an-
ion generation (72, 81). Hence, statins may act by inhib-
iting superoxide anion formation and subsequent LDL
oxidation by an NAPDH oxidase in activated monocy-
tes which requires assembly of various cytosolic com-
ponents including small GTP-binding proteins (67, 69).
Consistently, intake of the antioxidant vitamin C has
been demonstrated to prevent the increased CD11b-
dependent adhesiveness of monocytes from smokers
(73), which may involve similar oxidative pathways.
The finding that reductions in relative risk of CHD after
simvastatin reported in the 4S trial do not significantly
differ between quartiles for any lipid variable (62) im-
plies effects on mechanisms involved in atherogenesis
other than cholesterol lowering. Moreover, the efficacy
of pravastatin in the REGRESS study (64) is reduced by
smoking, which increases oxidative stress and mono-
cyte adhesiveness (73). In conclusion, the reduction of
monocyte CD11b expression and CD11b-dependent ad-
hesiveness to endothelium by statins provides a novel
mechanism of action of these compounds and may ex-
plain beneficial effects in the prevention and treatment
of CHD (62, 63). Inhibition of leukocyte adhesion and
chemotaxis (73, 82, 83) highlights actions of statins
which are not related to their cholesterol lowering ef-
fects but may be due to interference with cellular iso-
prenoid metabolism or prenylation-dependent pro-
cesses. As summarized in Table 1, other direct vascular
effects of statins have emerged, i.e. reduction of platelet
aggregation (84), inhibition of smooth muscle cell pro-
liferation and migration (85), upregulation of endothe-
lial NO synthetase (86) and inhibition of metalloprotease
secretion (87). Our findings may be crucial for clinical
benefits of statins, and may represent a novel anti-in-
flammatory paradigm for the mechanisms of action by
this class of drugs (88), which warrants further detailed
investigation with respect to leukocyte biology.
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